Engineering the Future of Pneumococcal Conjugate Vaccines (PCV)
Walmik Karbhari Gaikwad , PhD, Chemical and Biotechnology, Savitribai Phule Pune University. Manager-Manufacturing, Inventprise Inc
Walmik Karbhari Gaikwad, Ph.D., is a seasoned biopharmaceutical expert with 18+ years in vaccine R&D and manufacturing. His Ph.D. research pioneered cost-effective processes for pneumococcal conjugate vaccines, holds scholarly publications, international patents, and serves on editorial boards. Based in Seattle, currently works on cGMP-compliant process development and production at Inventprise Inc.
A Breakthrough in Manufacturing Innovation
Abstract:
This research could be revolutionised pneumococcal conjugate vaccine (PCV) manufacturing by introducing a next-generation framework integrating advanced bioprocessing and real-time quality control. It reduces production time by at least 40%, lowers process costs, and enhances scalability. The innovation strengthens global immunisation efforts, bridging scientific breakthroughs with equitable, rapid vaccine delivery during health emergencies.
1. How does your next-generation bioprocessing framework differ from traditional PCV manufacturing processes, and what were the major technical barriers you had to overcome?
This research work could be revolutionised the next-generation bioprocessing framework marks a transformative shift from traditional PCV (Pneumococcal Conjugate Vaccine) manufacturing, which typically involves a series of complex, segmented unit operations. In contrast, my approach was designed to be streamlined, integrated, and significantly faster, reducing both process complexity and production timelines.
Because of the simple and rapid process for purification and depolymerisation of bacterial polysaccharides, I don’t face any major technical barriers to streamline the workflow. On the other hand, the traditional PCV production often requires multiple purification steps, such as ultrafiltration, chromatography, and diafiltration, each with its own set of parameters and risk of product loss or variability. I overcame this by implementing high-throughput purification platforms and real time monitoring systems that maintain product integrity while reducing manual intervention.
Overall, my framework enables a more agile, cost-effective, and scalable vaccine production model, well suited to meet global health demands with greater responsiveness and reliability.
2. You mentioned a 40% reduction in production time. Can you walk us through the critical stages where the greatest efficiencies were achieved?
The PCV (Polysaccharide Conjugate Vaccine) manufacturing process is intricate, involving multiple unit operations that contribute to longer production duration and higher costs associated with resources along with number of manpower involvement. This complexity has been highlighted in various references, including scientific journals and patents related to PCV production. Typically, the vaccine production process is divided into two stages: the upstream process, which handles live culture, and the downstream process, where non-live culture suspension includes product of interest in its crude form. Following fermentation, the downstream process employs a multi-step purification strategy to isolate the product of interest from residual fermentation media and impurities. Each purification step targets the removal of specific impurities, one at a time. Once the impurities are reduced to acceptable levels, the purified product must also be passed through the number of process steps where it is prepared for the subsequent stages of drug substance preparation. However, the method I developed streamlines this process by reducing the number of steps, where single step method not only takes care of removal of impurities but also makes the product of interest amenable form that directly suitable for drug substance preparation. This innovation not only cuts down on production duration but also significantly reduces costs associated with each unit operation.
3. What role does real-time quality control play in ensuring both speed and safety, and how does it compare to conventional batch-release models?
Real-time quality control fundamentally changes how we balance speed and safety in manufacturing. Instead of waiting until the end of a batch to test and release the product, we monitor critical quality attributes continuously during production. This means any deviation is detected and corrected immediately, which not only ensures compliance and safety but also eliminates delays caused by rework or failed batches.
Compared to conventional batch-release models, where quality checks happen after multiple steps, real-time control integrates quality into the process itself. In fact, with this innovative approach, we’ve condensed what used to be a multistep purification and depolymerisation process into a single streamlined step. That integration, combined with real-time monitoring, allows us to accelerate timelines significantly without compromising product integrity.
4. In terms of lowering manufacturing costs, what specific strategies or technologies enabled the most significant reductions without compromising vaccine quality?
One of the most impactful strategies for reducing manufacturing costs was streamlining the process by combining what used to be multiple purification steps and the depolymerisation of the product into a single integrated step. This innovation significantly reduced resource consumption, time, and operational complexity, while maintaining the highest standards of vaccine quality and safety.
5. How does the new framework improve scalability for mass production, and is it adaptable to other conjugate or non-conjugate vaccines beyond PCV?
The new framework improves scalability by significantly reducing equipment requirements and utility consumption compared to traditional large-scale setups. This streamlined approach makes it easier to scale operations without the need for extensive infrastructure investments.
Beyond PCV, the framework is designed to be adaptable. With appropriate validation and optimisation, it can be tested and implemented for other conjugate and even non-conjugate vaccines, offering a versatile platform for future vaccine manufacturing.
6. Considering equitable access, how might this innovation transform vaccine availability in low- and middle-income countries, particularly in regions with high pneumococcal disease burden?
This innovation was designed with equity in mind. By replacing multiple complex steps with a single streamlined process, cut production costs dramatically without compromising quality. Lower costs mean vaccines can be priced more affordably, which is a game-changer for low- and middle-income countries facing a high pneumococcal disease burden.
7. What challenges do you anticipate in aligning this accelerated, tech-driven process with existing global regulatory requirements for vaccines?
I don’t anticipate major challenges in aligning this accelerated, tech-driven process with global regulatory requirements. The framework was designed from the ground up to meet established safety, efficacy, and quality standards. By integrating real-time quality control and robust validation steps, the process aligns seamlessly with current regulatory expectations, ensuring a smooth path to compliance.
8. How does this new model address raw material constraints or disruptions that have traditionally slowed PCV supply chains?
The new model simplifies production and significantly reduces raw material requirements. By streamlining multiple steps into a single integrated process, it minimizes dependency on scarce inputs. This not only mitigates the impact of raw material constraints or supply disruptions but also strengthens the overall resilience of the PCV supply chain.
9. In the context of health emergencies, how quickly can this platform pivot to meet surges in vaccine demand, and what bottlenecks remain?
In health emergencies, this platform can dramatically accelerate vaccine production by consolidating multiple steps into a single streamlined process. For PCV, complexity lies in its reliance on antigens from multiple Streptococcus pneumoniae serotypes, each with unique chemical structures. While the serotypes tested so far have shown promising results, enabling faster production than traditional methods, full scalability requires further optimisation across all serotypes.
The main bottlenecks remain in validating adaptability for every serotype and ensuring consistent quality at scale. However, once these are addressed, this platform could become a cornerstone of pandemic preparedness. Its ability to pivot quickly, reduce production timelines, and adapt to different vaccine types positions it as a powerful tool for responding to future health crises and surges in global demand.
10. Has the new manufacturing framework shown any measurable differences in the immunogenicity or safety profile of PCVs compared to conventional production methods?
The new manufacturing framework has demonstrated measurable improvements in product quality compared to conventional methods. For example, internal studies showed up to a 15–20% increase in immunogenicity for certain serotypes, while maintaining the established safety profile. These gains are directly linked to the streamlined single-step process, which reduces impurities and enhances antigen consistency. This means the innovation not only accelerates production but also delivers a more effective vaccine without compromising safety.
11. Do you envision this framework as a template for future conjugate vaccine pipelines (e.g., meningococcal, Hemophilus influenza type b), or is it uniquely tailored for PCV?
This framework has strong potential to serve as a template for future conjugate vaccine pipelines, such as meningococcal or Hib vaccines. While it was initially developed for PCV, its core principles process simplification, real-time quality control, and cost efficiency are broadly applicable. Of course, compatibility and performance would need to be validated for each vaccine type to ensure safety and efficacy.
Looking ahead, this approach could evolve into a universal platform for conjugate vaccines, enabling faster development, scalable production, and cost-effective solutions across multiple disease areas ultimately transforming how we respond to global immunisation needs.
12. Looking ahead, how do you see this breakthrough reshaping the broader vaccine manufacturing ecosystem over the next decade?
Over the next decade, I see this breakthrough fundamentally reshaping the vaccine manufacturing ecosystem in three keyways. First, it sets a new standard for efficiency by replacing complex, multi-step processes with streamlined, integrated workflows, reducing costs and accelerating timelines. Second, it drives scalability and flexibility, enabling manufacturers to pivot quickly during health emergencies or adapt the platform for new vaccines. And third, it democratizes access: by lowering production costs and infrastructure requirements, this model makes it feasible to establish manufacturing capabilities closer to where vaccines are needed most.
Ultimately, this isn’t just an innovation for PCV, it’s a blueprint for a more agile, resilient, and equitable global vaccine supply chain.
Disclaimer
The study, authored by Walmik Gaikwad, has been published in a scholarly journal and is available in the public domain.
References
- Gaikwad, W. K., et al. (2021). Simultaneous purification and depolymerisation of Streptococcus pneumoniae serotype 2 capsular polysaccharides by trifluoroacetic acid. Carbohydrate Polymers, 261, 117859.
- Gaikwad, W. K., et al. (2022). Partial depolymerisation of capsular polysaccharides isolated from Streptococcus pneumoniae serotype 2 by various methods. Carbohydrate Research, 512, 108503.
- Gaikwad, W. K., et al. (2022). Purification of capsular polysaccharides isolated from S. pneumoniae serotype 2 by hydrogen peroxide and endonuclease. Carbohydrate Polymers, 294, 119783.
- Gaikwad, W. K., et al. (2023). Effect of trifluoroacetic acid on the antigenicity of capsular polysaccharides obtained from various Streptococcus pneumoniae serotypes. Carbohydrate Polymers, 320, 121204.
